The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions FDA Compliance for Peptide Therapy and BPC 157 Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Banned: Key Facts on the Latest FDA Decision